This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report.
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report.
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report.
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report.
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report.
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.
